Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Maintenance Tislelizumab Combined With Capecitabine to Treat Metastatic Colorectal Cancer With No Evidence of Disease

NCT05360277 is registered in ClinicalTrials.gov with Yanhong Deng as lead sponsor.

NCT NCT05360277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05360277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Maintenance Tislelizumab Combined With Capecitabine to Treat Metastatic Colorectal Cancer With No Evidence of Disease
Lead sponsor
Yanhong Deng
Phase
Phase 2
Overall status
Recruiting
Start date
August 22, 2023
Completion date
November 30, 2027
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer，ned